TITLE

COMMENTARY: Review: Atypical antipsychotic drugs increase risk for death in dementia

AUTHOR(S)
Hirsch, Calvin
PUB. DATE
March 2006
SOURCE
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p36
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents a study which reveals that atypical antipsychotic drugs increase risk for death in dementia. Researchers substantiate an April 2005 advisory from the U.S. Food and Drug Administration about increased mortality in older patients with dementia given atypical Atypical antipsychotic drugs (APDs). According to the researcher, atypical APDs will cause 1 death for every 85 patients treated, or 1 excess death for every 12 patient-years of treatment. The risks associated with such conventional APDs as haloperidol and the phenothiazines are even greater.
ACCESSION #
20297593

 

Related Articles

  • Drug-induced symptoms. Sandroff, Ronni // Consumer Reports on Health;Jul2005, Vol. 17 Issue 7, p2 

    Reports on the issuance of a public health advisory about the use of a typical antipsychotic drugs in older people with dementia, by the U.S. Food and Drug Administration (FDA). Lists of drugs included in the advisory; Reason for the review of drugs not included in the list; Protection to older...

  • Off-label atypical antipsychotic use could be deadly.  // Reactions Weekly;4/16/2005, Issue 1047, p3 

    Reports on a Public Health Advisory issued by the U.S. Food and Drug Administration (FDA) to highlight the finding of an increased rate of death in elderly patients with dementia receiving atypical antipsychotics for behavioral disorders. Rate of death in elderly patients with dementia; Request...

  • Boxed warning now required for antiphychotics for elderly with dementia. Elliott, William T. // Primary Care Reports;Aug2008, Vol. 14 Issue 8, p1 

    The article reports on a boxed warning being required by the U.S. Food and Drug Administration (FDA) for conventional antipsychotics regarding an increased risk of mortality in elderly patients treated for dementia-elated psychosis. The new warning entails medication such as haloperidol,...

  • FDA Warns Antipsychotic Drugs May Be Risky for Elderly. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;5/25/2005, Vol. 293 Issue 20, p2462 

    Reports the U.S. Food and Drug Administration warned that antipsychotic drugs can increase the death rate in elderly dementia patients. Information from studies on olazapine, aripiprazole, risperidone, and quetiapine; Indication two other atypical antipsychotics approved by the FDA, clozapine...

  • News in brief ...  // PharmacoEconomics & Outcomes News;7/16/2005, Issue 482, p8 

    Presents the results of a study regarding the link between the use of antipsychotics or concomitant use of psychotropics with an increased mortality rate in elderly patients with dementia. Reference to a study by S. Hartikainen et al published in a July 2005 issue of "International Clinical...

  • Review: Atypical antipsychotic drugs increase risk for death in dementia.  // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p36 

    This article presents a study which reveals that atypical antipsychotic drugs increase risk for death in dementia. 5 placebo controlled trials (RCT) with 16 comparisons met the selection criteria. 9 RCTs were unpublished. 87% of patients had Alzheimer disease. Patients were nursing home...

  • CMS Seeks to Reduce Antipsychotic Use in Nursing Home Residents With Dementia. Mitka, Mike // JAMA: Journal of the American Medical Association;7/11/2012, Vol. 308 Issue 2, p119 

    The article presents information on the decision of Centers for Medicare & Medicaid Services (CMS) related to the improper antipsychotic medications for dementia in the patients of various nursing homes in the U.S. It informs that in the year 2005 the U.S. Food and Drug Administration (FDA) has...

  • Boxed warning now required for antiphychotics for elderly with dementia.  // Primary Care Reports;Aug2008 Pharmacology Watch, p1 

    This article reports on a policy issued by the U.S. Food and Drug Administration in 2008 requiring a boxed warning for conventional antipsychotics. The policy concerns with an increased risk of mortality in elderly patients treated for dementia-elated psychosis. The policy expands the warning on...

  • Boxed warning now required for antiphychotics for elderly with demetia. Elliott, William T. // Clinical Oncology Alert;Aug2008 Pharmacology Watch, p1 

    The article deals with the requirement of the U.S. Food and Drug Administration (FDA) for conventional antipsychotics for the elderly with dementia to have a boxed warning. The move was noted to expand the warning requirement to include medication such as haloperidol, thioridazine and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics